Stocktoria
Vanda Pharmaceuticals Inc. VNDA
Vanda Pharmaceuticals Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $216.1M | $198.8M | $192.6M | $254.4M | $268.7M | $248.2M | $227.2M | $193.1M | $165.1M | $146.0M |
| R&D expense | $109.3M | $74.4M | $76.8M | $85.8M | $75.4M | $55.6M | $48.6M | $43.6M | $38.5M | $29.2M |
| SG&A expense | $238.0M | $146.4M | $112.9M | $136.5M | $124.0M | $140.5M | $129.7M | $105.8M | $123.8M | $99.8M |
| Operating income | -$151.2M | -$40.7M | -$14.0M | $6.3M | $42.2M | $27.2M | $22.8M | $21.7M | -$16.9M | -$18.6M |
| Income tax | $81.8M | -$4.0M | $3.8M | $5.0M | $9.2M | $8.3M | -$86.5M | $138,000 | $136,000 | $104,000 |
| Net income | -$220.5M | -$18.9M | $2.5M | $6.3M | $33.2M | $23.3M | $115.6M | $25.2M | -$15.6M | -$18.0M |
| EPS (diluted) | $-3.74 | $-0.33 | $0.04 | $0.11 | $0.58 | $0.42 | $2.11 | $0.48 | $-0.35 | $-0.41 |
| Operating cash flow | -$109.4M | -$15.8M | $12.8M | $32.0M | $64.2M | $51.8M | $45.9M | $30.0M | -$2.0M | -$8.1M |
| Free cash flow | -$110.4M | -$16.2M | $12.4M | $31.3M | $63.7M | $50.0M | $44.9M | $29.6M | -$3.6M | -$9.5M |
| Cash & equivalents | $84.9M | $102.3M | $135.8M | $135.0M | $52.1M | $61.0M | $45.1M | $61.0M | $33.6M | $40.4M |
| Inventory | $1.9M | $1.7M | $1.4M | $1.2M | $1.0M | $1.3M | $1.1M | $994,000 | $840,000 | $779,000 |
| Total assets | $488.9M | $656.2M | $648.4M | $634.2M | $593.8M | $533.5M | $483.7M | $332.1M | $205.4M | $210.4M |
| Total liabilities | $161.8M | $117.7M | $103.5M | $107.0M | $88.9M | $80.2M | $72.8M | $56.7M | $74.0M | $79.0M |
| Shareholders' equity | $327.2M | $538.5M | $544.9M | $527.2M | $504.9M | $453.3M | $410.9M | $275.4M | $131.4M | $131.3M |
Growth · year-over-year · Revenue CAGR 4.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +8.7% | +3.2% | -24.3% | -5.3% | +8.3% | +9.2% | +17.6% | +17.0% | +13.1% | +32.8% |
| Net income growth | — | -853.3% | -60.0% | -81.1% | +42.1% | -79.8% | +358.4% | — | — | — |
| EPS growth | — | -925.0% | -63.6% | -81.0% | +38.1% | -80.1% | +339.6% | — | — | — |
| Free cash flow growth | — | -230.8% | -60.3% | -50.8% | +27.4% | +11.2% | +51.7% | — | — | -195.8% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.